MA50242A - Modulateurs du récepteur hormonal pour le traitement d'états et de troubles métaboliques mutagènes et fibrotiques - Google Patents
Modulateurs du récepteur hormonal pour le traitement d'états et de troubles métaboliques mutagènes et fibrotiquesInfo
- Publication number
- MA50242A MA50242A MA050242A MA50242A MA50242A MA 50242 A MA50242 A MA 50242A MA 050242 A MA050242 A MA 050242A MA 50242 A MA50242 A MA 50242A MA 50242 A MA50242 A MA 50242A
- Authority
- MA
- Morocco
- Prior art keywords
- mutagenic
- fibrotic
- disorders
- treatment
- receptor modulators
- Prior art date
Links
- 230000003176 fibrotic effect Effects 0.000 title 1
- 230000003054 hormonal effect Effects 0.000 title 1
- 230000002503 metabolic effect Effects 0.000 title 1
- 231100000219 mutagenic Toxicity 0.000 title 1
- 230000003505 mutagenic effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762558858P | 2017-09-14 | 2017-09-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA50242A true MA50242A (fr) | 2020-07-22 |
Family
ID=63714148
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA050242A MA50242A (fr) | 2017-09-14 | 2018-09-14 | Modulateurs du récepteur hormonal pour le traitement d'états et de troubles métaboliques mutagènes et fibrotiques |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US11753410B2 (https=) |
| EP (1) | EP3681881B1 (https=) |
| JP (2) | JP7271513B2 (https=) |
| CN (1) | CN111655680B (https=) |
| MA (1) | MA50242A (https=) |
| WO (1) | WO2019055808A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA55632A (fr) | 2016-08-23 | 2022-02-16 | Ardelyx Inc | Procédé de preparation de modulateurs du récepteur hormonal pour le traitement d'états et de troubles métaboliques |
| US11091482B2 (en) | 2016-08-23 | 2021-08-17 | Ardelyx, Inc. | Isoxazolyl-carbonyloxy azabicyclo[3.2.1]octanyl compounds as FXR activators |
| CN110128432B (zh) | 2018-02-02 | 2021-03-02 | 广东东阳光药业有限公司 | 含氮三环化合物及其在药物中的应用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1228288B (it) | 1989-01-09 | 1991-06-07 | Zambon Spa | Composti ad attivita' antiserotoninica |
| US5262564A (en) | 1992-10-30 | 1993-11-16 | Octamer, Inc. | Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents |
| TW200906823A (en) | 2007-07-16 | 2009-02-16 | Lilly Co Eli | Compounds and methods for modulating FXR |
| EP2289883A1 (en) | 2009-08-19 | 2011-03-02 | Phenex Pharmaceuticals AG | Novel FXR (NR1H4) binding and activity modulating compounds |
| JP2014500319A (ja) | 2010-12-20 | 2014-01-09 | アイアールエム・リミテッド・ライアビリティ・カンパニー | ファルネソイドｘ受容体を調節するための組成物および方法 |
| WO2012087520A1 (en) | 2010-12-20 | 2012-06-28 | Irm Llc | Compositions and methods for modulating farnesoid x receptors |
| CU24152B1 (es) * | 2010-12-20 | 2016-02-29 | Irm Llc | 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr |
| JP2014533258A (ja) | 2011-11-15 | 2014-12-11 | ゼンション・リミテッドＸｅｎｔｉｏｎ Ｌｉｍｉｔｅｄ | カリウムチャネル阻害剤としてのチエノ［２，３−ｃ］ピラゾールの使用 |
| EP3034501A1 (en) * | 2014-12-17 | 2016-06-22 | Gilead Sciences, Inc. | Hydroxy containing FXR (NR1H4) modulating compounds |
| US20170368038A1 (en) * | 2014-12-18 | 2017-12-28 | Novartis Ag | Azabicyclooctane derivatives as fxr agonists for use in the treatment of liver and gastrointestinal diseases |
| TWI698430B (zh) | 2015-02-13 | 2020-07-11 | 南北兄弟藥業投資有限公司 | 三環化合物及其在藥物中的應用 |
| MA55632A (fr) | 2016-08-23 | 2022-02-16 | Ardelyx Inc | Procédé de preparation de modulateurs du récepteur hormonal pour le traitement d'états et de troubles métaboliques |
| US11091482B2 (en) | 2016-08-23 | 2021-08-17 | Ardelyx, Inc. | Isoxazolyl-carbonyloxy azabicyclo[3.2.1]octanyl compounds as FXR activators |
| KR102400183B1 (ko) | 2017-07-06 | 2022-05-18 | 수안주 바이오파마슈티컬 컴퍼니 리미티드 | Fxr 작용제 |
-
2018
- 2018-09-14 JP JP2020515081A patent/JP7271513B2/ja active Active
- 2018-09-14 CN CN201880072464.XA patent/CN111655680B/zh active Active
- 2018-09-14 EP EP18779987.9A patent/EP3681881B1/en active Active
- 2018-09-14 MA MA050242A patent/MA50242A/fr unknown
- 2018-09-14 WO PCT/US2018/051122 patent/WO2019055808A1/en not_active Ceased
- 2018-09-18 US US16/647,385 patent/US11753410B2/en active Active
-
2023
- 2023-03-01 JP JP2023031187A patent/JP2023065577A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US11753410B2 (en) | 2023-09-12 |
| CN111655680A (zh) | 2020-09-11 |
| US20210380585A1 (en) | 2021-12-09 |
| EP3681881A1 (en) | 2020-07-22 |
| JP2020534275A (ja) | 2020-11-26 |
| EP3681881B1 (en) | 2022-11-02 |
| WO2019055808A1 (en) | 2019-03-21 |
| JP2023065577A (ja) | 2023-05-12 |
| CN111655680B (zh) | 2024-03-05 |
| JP7271513B2 (ja) | 2023-05-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA46052A (fr) | Modulateurs du récepteur hormonal pour le traitement d'états et de troubles métaboliques | |
| MA49279A (fr) | Compositions d'anticorps optimisées pour le traitement de troubles oculaires | |
| EP3773543A4 (en) | COMBINATION THERAPIES FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS AND RELATED DISEASES | |
| EP3481387A4 (en) | METHOD AND COMPOSITIONS FOR TREATING EPILEPTIC DISEASES | |
| EP3448398A4 (en) | COMPOSITIONS AND METHODS FOR TREATING SKIN DISEASES | |
| EP3423047A4 (en) | COMPOSITIONS OF CB2 RECEPTOR SELECTIVE AGONISTS FOR THE TREATMENT OF MENTAL DISEASES | |
| EP3704108A4 (en) | COMPOUNDS AND COMPOSITIONS FOR TREATMENT OF HEMATOLOGICAL DISORDERS | |
| MA45150A (fr) | Modulateurs du récepteur adrénergique-bêta-3 utiles pour le traitement et la prevention de troubles associes a ce dernier | |
| EP3465212A4 (en) | REGULAR FLORAL REGULATION FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | |
| EP3180022A4 (en) | IMPROVED EXPRESSION CASSETTE FOR THE PACKAGING AND EXPRESSION OF VARIANT FACTOR VIII FOR THE TREATMENT OF HEMOSTATIC DISEASES | |
| EP3328376A4 (en) | Methods and compositions for treating metabolic reprogramming disorders | |
| MA47207A (fr) | Composés utiles pour le traitement de troubles du tractus digestif | |
| MA50391A (fr) | Nouveaux composés et compositions pharmaceutiques associées pour le traitement de troubles inflammatoires | |
| EP3468532A4 (en) | DISTRIBUTION DEVICE AND PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF RHINITIS | |
| MA51056A (fr) | Compositions et méthodes pour le traitement d'affections métaboliques | |
| EP3368088C0 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PEROXISOMAL DISEASES AND LEUKODYSTROPHIES | |
| EP3445352A4 (en) | COMPOSITIONS FOR THE TREATMENT OF HYPERKERATOSIS DISEASES | |
| MA42953A (fr) | Composés et compositions pour le traitement de troubles oculaires | |
| EP3743091A4 (en) | PROCEDURES AND COMPOSITIONS FOR TREATMENT OF ANGIOGENIC DISORDERS USING ANTI-VEGF AGENTS | |
| EP3723768A4 (en) | COMPOUNDS FOR TREATMENT AND PREVENTION OF EXTRACELLULAR HISTONE-MEDIATED PATHOLOGIES | |
| EP3500308A4 (en) | INHIBITION OF THE SPHINGOSIN-1-PHOSPHATE RECEPTOR FOR TREATING AND PREVENTING LYMPHEDEMES | |
| EP3856168A4 (en) | COMPOSITION AND USE FOR THE TREATMENT OF PARKINSON'S DISEASE AND RELATED DISEASES | |
| EP3442554A4 (en) | COMPOSITIONS AND METHODS OF TREATING DISEASES RELATED TO NEOVASCULARIZATION | |
| EP4059503A4 (en) | THERAPEUTIC AND PROPHYLACTIC FOR FUNCTIONAL GASTROINTESTINAL DISORDERS AND XEROSTOMIA | |
| MA41985A (fr) | Composition pour le nettoyage du côlon et le traitement de troubles gastro-intestinaux |